LAM/TSC Seminar Series
June 5, 2008
The VHL Tumor Suppressor Protein: Cancer and Oxygen Sensing
Speaker: William Kaelin, MD (DFCI/HMS)
Discussant: Leif Ellisen, MD, PhD (MGH Cancer Center/HMS)
May 29, 2008
TSC2 and glucose transport: Implications for treating LAM and TSC
Speaker: Ray Yeung, MD, FRCS (C), FACS (University of Washington)
Discussant: Lewis Cantley, PhD (BIDMC/HMS)
April 17, 2008
Development of novel PI3 Kinase and MTOR Inhibitor
Speaker: William Sellers, MD (Novartis)
Discussant: Matthew Kulke, MD (DFCI/HMS)
March 13, 2008
Melanocytic markers in non-melanoma malignancies: Role of the MiT transcription factor" & Why do LAM Cells express melanocytic markers?
Speakers: David Fisher, MD, PhD (MGH/HMS) & Elizabeth Henske, MD (FCCC)
Discussant: Andrew Wagner, MD, PhD (DFCI/HMS)
February 28, 2008
Molecular mechanisms and the genetics underlying the pathogenesis of human cancer.
Speaker: Pier Paolo Pandolfi, MD, PhD (BIDMC/HMS)
Discussants: Elizabeth Thiele, MD, PhD (Massachusetts General Hospital/HMS), Brendan Manning, PhD (Harvard School of Public Health)
January 24, 2008
Critical re-cap of this week's NCI/NIH-NINDS mTOR workshop & Review of NEJM articles & letters re: LAM & TSC
Speakers: Mustafa Sahin, MD, PhD; Vijaya Ramesh, PhD; David Kwiatkowski, MD, PhD; Sandra Dabora, MD, PhD; Elizabeth Thiele, MD, PhD; Po-Shun Lee, MD; Geraldine Finlay, MD
November 1, 2007
Lymphangiogenesis: the state of the art and translational medicine; & Lymphangiogenesis and Hormonal modulation in LAM
October 11, 2007
Rewiring and misfiring: Signaling defects triggered by loss of the TSC tumor suppressors
September 20th, 2007
Regulation of cell growth and protein synthesis by mTOR
June 21, 2007
Statins: Therapeutic agents for TSC2 null states
MED28 (magicin) Functions as a Transcriptional Repressor of Smooth Muscle Differentiation at the Stem Cell Level: Implications for LAM and Other Smooth Muscle Tumors
May 10, 2007
Hypoxia, Stem Cells, and Tumor Progression
Hypoxia regulation of TSC/mTOR signaling
April 12, 2007
Special Panel: Renal AMLs in LAM/TSC
What can basic science teach us about improved clinical care?
What can diagnostic dilemmas teach us about the basic science of LAM/TSC?
March 15, 2007
New Developments in the Neurobiology of the Tuberous Sclerosis Complex
Molecular Insights into the Effects of Therapy on Malignant Gliomas
February 1, 2007
New Therapeutic Targets for Combination Therapy with Rapamycin in TSC and LAM
January 18, 2007
mTOR dependent regulation of growth and metabolism: Implications for the treatment of LAM/TSC
December 14, 2006
Does Estrogen Synthesize with mTOR activation to promote LAM cell metastasis?
November 30, 2006
LAM Research: New Insights & Unanswered Questions
Dr. Joel Moss (NIH-NHLBI) discussed key challenges in research on Lymphangioleiomyomatosis (LAM). Dr Myles Brown and Dr. George Demetri discussed and facilitated exchange on topics and potential therapeutic interventions.
October 26, 2006
mTOR Function and Regulation: Implications for the treatment of Lymphangioleiomyomatosis (LAM) & Tuberous Sclerosis Complex (TSC)
Dr. David Sabatini is Associate Professor of Biology at MIT. Dr. Brendan Manning is Associate Professor of Genetics and Complex Disease at the Harvard School of Public Health.
June 22, 2006
Kun-Liang Guan, Ph.D. from the University of Michigan whose work on signaling biochemistry and TSC1/TSC2 is highly relevant to LAM/TSC will present.
Lew Cantley, Ph.D (BIDMC, HMS) who has done seminal work on P13Kinase and protein kinase signaling pathways is highly relevant to these diseases will serve as discussant and moderator.
May 18, 2006
LAM is a disease that mainly affects women. This seminar will focus on the links between estrogen and LAM.
Dr. David Kwiatkowski, MD, PhD
Myles Brown, MD (Dana-Farber/HMS) will speak about his work on estrogen in cancer and LAM.
David Kwiatkowski, MD, PhD. (BWH/Dana-Farber/HMS) will review data on estrogen in mouse models and LAM and some new results from mutational studies of TSC1/TSC2.
February 16, 2006
Cell-specific abnormalities in neurotransmitter receptor expression in TS lesions and Regulations of TSC proteins in the CNS
Dr. Jensen is a Senior Associate in Medicine at Children's Hospital Boston and Associate Professor of Neurology, Harvard Medical School Dr. Ramesh is an Assistant in Genetics, Molecular Genetics Unit MGH and Associate Professor, Dept. of Neurology HMS.
January 26, 2006
Dr. Bernardo Sabatini, MD, PhD
Dr. Elizabeth Thiele MD, PhD
Tuberous Sclerosis Complex and the Brain
Dr Thiele spoke about the neurologic involvement in TSC followed by a talk on the basic science by Dr. Sabatini, who will also facilitated discussion.
December 1, 2005
Current and future trials of mTOR inhibitors in patients with TSC and LAM
Dr. Frank McCormack
Director, Division of Pulmonary and Critical Care at the University of Cincinnati and Chair of the LAM Foundation Scientific Advisory Board
November 3, 2005
Can lessons from antiangiogenic therapy of cancer be applied to LAM?
Dr. Judah Folkman
Dr. Marsha Moses
Dr. Folkman spoke about his recent work on LAM with Dr. Marsha Moses, Associate Professor of the Department of Surgery at Harvard Medical School / Vascular Biology Program at Children's Hospital Boston
October 6, 2005
Professor at Harvard Medical School
Dr. Avruch spoke about his work on kinase signaling pathways and recent results on the Rheb-mTOR interaction.
LAM Treatment Alliance
E-mail: info@lamtreatmentalliance.org
Mailing Address: 87 Garden Street; Cambridge, MA 02138; USA
Phone: +1 (617) 460-7339
Fax: +1 (617) 864-0614
Sponsors, Partners and Supporters
Harvard Medical SchoolDepartment of Continuing Education
Brigham and Women's Hospital
Dana-Farber Cancer Institute
National Heart Lung and Blood Institute
MassachusettsGeneral Hospital
National Disease Research Interchange
Foley Hoag
Starbucks Coffee